In 2005, the quadrivalent meningococcal vaccine MCV4 (Menactra; Sanofi Pasteur) — which contains N. meningitidis serogroup A, C, Y and W-135 polysaccharides conjugated individually to diphtheria ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

University of Maryland School of Medicine (UMSOM) researchers helped conduct an important new global health study that found a vaccine that protects against five strains of meningitis prevalent in sub ...

Meningitis (Men Quad/Conjugate, MCV4) One dose on or after 16th birthday if 23 years or younger. Meningococcal B (Separate from Meningitis) Two doses of the same brand (Bexsero or Trumenba) if 23 ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

FDA Approves 5-in-1 Vaccine Against Meningococcal DiseaseThe FDA has approved Penmenvy, a new 5-in-1 shot to protect against meningococcal infections or invasive meningococcal disease (IMD ...

Medically reviewed by Kristie Reed, PharmDMedically reviewed by Kristie Reed, PharmD The Centers for Disease Control and ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

Current levels of vaccine coverage for adolescents fall short of national goals and recommendations, placing teens and others at risk for many vaccine-preventable infections. To improve coverage ...